首页> 外文期刊>Neuroscience and behavioral physiology >Neuroprotective therapy with citicoline (Ceraxon) in patients with ischemic stroke
【24h】

Neuroprotective therapy with citicoline (Ceraxon) in patients with ischemic stroke

机译:胞磷胆碱(Ceraxon)对缺血性中风患者的神经保护治疗

获取原文
获取原文并翻译 | 示例
       

摘要

The dynamics of neurological symptoms were assessed using the Scandinavia Stroke Scale and functional disease outcomes with the Barthel index and modified Rankin scale in 89 patients during the acute period of ischemic stroke of moderate severity, whose treatment included citicoline (Ceraxon) i.v. and p.o. The results were compared with those from a reference group (52 patients) selected in terms of clinical and demographic parameters, who received similar treatment without citicoline. By discharge from hospital (days 21-24 of illness), there was significantly (p < 0.05) greater recovery in the study group. The efficacy of citicoline was significantly (p < 0.05) greater in patients aged less than 70 years and when citicoline was given in the first hours of illness.
机译:使用Scandinavia中风量表和Barthel指数和改良的Rankin量表对89例中度缺血性中风急性期患者的神经系统症状动态进行了评估,这些患者的治疗包括胞磷胆碱(Ceraxon)i.v.和p.o.将结果与根据临床和人口统计学参数选择的参考组(52例患者)的结果进行了比较,他们在没有胞磷胆碱的情况下接受了类似的治疗。通过出院(患病第21至24天),研究组的恢复显着(p <0.05)。在年龄小于70岁的患者中以及在发病的头几个小时使用胞磷胆碱时,胞磷胆碱的疗效显着(p <0.05)更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号